- Home
- STRW vs ANTX Comparison
STRW vs ANTX Comparison
Compare STRW & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STRW | ANTX |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 192.0M | 172.9M |
| IPO Year | 2019 | 2022 |
Fundamental Metrics
Financial Performance| Metric | STRW | ANTX |
|---|---|---|
| Price | $13.85 | $5.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $13.88 | $2.00 |
| AVG Volume (30 Days) | 45.2K | ★ 194.3K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | ★ 5.17% | N/A |
| EPS Growth | 5.26 | ★ 32.56 |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $154,999,000.00 | N/A |
| Revenue This Year | $8.52 | N/A |
| Revenue Next Year | $3.95 | N/A |
| P/E Ratio | $42.00 | ★ N/A |
| Revenue Growth | ★ 32.41 | N/A |
| 52 Week Low | $11.11 | $1.00 |
| 52 Week High | $14.75 | $7.19 |
Technical Indicators
Market Signals| Indicator | STRW | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.42 | 59.63 |
| Support Level | $12.59 | $3.91 |
| Resistance Level | $14.75 | $7.05 |
| Average True Range (ATR) | 0.41 | 0.47 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 57.04 | 34.46 |
Price Performance
Historical ComparisonAbout STRW Strawberry Fields REIT Inc.
Strawberry Fields REIT Inc is a self-managed and self-administered company that specializes in the acquisition, ownership and triple-net leasing of skilled nursing facilities and other post-acute healthcare properties.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.